MIRACLE Medical Technology Act of 2025

This bill directs the U.S. health department to run a program with Israel to develop and deliver better health care products and services. It backs joint research, helps start-ups bring new tools to market, lines up rules between the two countries, strengthens telehealth, and works together on disease prevention and vaccine efforts. It also allows a U.S.-based collaboration center to coordinate this work .

Key points

• Who is affected: Patients, hospitals and clinics, researchers, and health tech companies in both countries, plus regulators like the FDA and Israel’s health ministry.
• What changes:
  • Joint research on medical devices, medicines (including biologics and genomics), digital health, and early clinical trials, with work toward a data‑sharing framework.
  • Support for start‑ups and innovation hubs, technology transfer, and steps to protect patient privacy and cybersecurity when sharing data.
  • Closer alignment of rules and protections, including intellectual property, possible mutual recognition of drug manufacturing standards, and expanded use of Project Orbis for faster cancer drug reviews.
  • Stronger telemedicine and better system‑to‑system connections between the two countries’ health systems.
  • Boosted U.S. manufacturing of biological products, including training workers, building supply‑chain backups, and supporting public‑private partnerships.
• When: The program must begin within 6 months after the bill becomes law, with $8 million per year authorized from 2026 through 2030.